title: Thrombosis in children with hematologic malignancies.
abstract: This review is based on pediatric reports (- January 2004) on the presence of symptomatic thrombosis in children with hematologic malignancies, mainly acute lymphoblastic leukemia, treated with different treatment protocols and associated with acquired and inherited prothrombotic risk factors (factor V G1691A, factor G20210A, MTHFR C677T genotypes, protein C, protein S, antithrombin, elevated levels of lipoprotein(a), and homocysteine). The interactions of treatment modalities, study designs, ethnical backgrounds and associated central lines are discussed. Based on the data presented here, we suggest the use of prednisone and E. coli asparaginase concomitantly administered in a leukemic patient suffering a prothrombotic risk factor to be responsible for the onset of venous thrombosis in the majority of cases. In addition, primary preventive anticoagulant/antithrombotic strategies are discussed.
authors: Department of Pediatrics, University of Halle, Germany.
authors: Rosemarie
authors: R
authors: Schobess
authors: Beate
authors: B
authors: Kempf-Bielack
authors: Dirk
authors: D
authors: Schwabe
authors: Ronald
authors: R
authors: Sträter
authors: Ulrike
authors: U
authors: Nowak-Göttl
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001798:Blood Proteins; D002648:Child; D019337:Hematologic Neoplasms / Q000097:blood* / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D019851:Thrombophilia / Q000209:etiology; D013927:Thrombosis / Q000209:etiology*
chemical_list: D000970:Antineoplastic Agents; D001798:Blood Proteins